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Abstract 
Most problematic infection haemodialysis (HD) are at higher risk for acquiring Hepatitis B virus (HBV) and 
Hepatitis C virus (HCV) infections than the general population.  
Patients and Methods 
This study was carried out between January 2018 until July 2018, a total of (60) blood samples were collected 
from hemodialysis patients. The samples tested against anti-HCV, HBsAg anti-HBS and anti-HBC IgM, using 
ELISA technique and determination HBV-DNA, HCV-RNA viral load by Real time polymerase chain reaction. 
Results 
Prevalence HCV RNA was 12(20%) out of 60 patients were RT-PCR positive for HCV RNA with viral load, up 
to 100.000, Copy/ml and 10(16.69%) out of 60 patients were RT-PCR positive for HBV DNA in both positive 
and negative HCV RNA patients group with average viral load more than 100.000 copy/ml., 3 Patients out of 12 
(25%) HCV RNA, positive patients were also positive for HBV DNA, while 40 (66%) out of 60 patients were 
anti-HBSAg positive, while the positivity of anti-HBCoIgM was 5 (50%). 
Conclusion 
The prevalence of co-infection hepatitis B and C was high in hemodialysis patients in Mosul district/Iraq 
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1. Introduction 
Although dialysis is the treatment of choice for end-stage renal failure, dialysis patient are at risk for contracting 
blood-borne infection, including hepatitis viruses HBV and HCV
 
[1]: viral hepatitis among dialysis patients is 
associated with significant severity and poor prognosis
 
[2] and both HBV and HCV synergize in accelerating the 
progression to hepatic anomalies
 
[3] , although some dispute any effect of combined HBV/HCV infection on 
acceleration of liver disease
 
[4]. Previous screening for HBV and HCV infection relied on serologic tool 
(HBsAg and anti-HCV for HCV), and change the liver enzymes [5]. In view of the false-negatives inherent in 
serology testing [5,6] this highlighted the need for accurate means of detecting HBV/HCV including polymerase 
chain reaction (PCR) [6,7]. Determination of the virus type and viral load serve an important diagnostic tool in 
the patients follow up and treatment [2,7]. There are very few reports on the prevalence of such dual infections 
in hemodialysis patients. The present study was undertaken to estimate the prevalence of HBV and HCV dual 
infection among hemodialysis patients. 
2. Patients and Methods 
Collected blood samples from 60 chronic hemodialysis patients in Mosul-Iraq to detect HCV and HBV infection 
in them, there were 40(66.6%) males and 20(33.3%) females and the average age of patients was 20-60 years. 
2.1 Enzyme linked immunosurbent assay (ELISA) 
Screening test for anti-HCV and HBSAg were performed using Anti-HVC ELISA kit (plasmatic UK) Anti-HBC 
and Anti-HBS test were also performed using ELISA kit (Bio kit, Spain). 
2.2 Polymerase chain reaction test 
2.3 RNA and DNA Extraction 
HCV RNA and HBV DNA were extraction using nucleic acid isolation kit (Omega Bio-tek). The test done 
according leaflet inside the kit.  
 Real time RCR tests. 
 Quantitative of HBV DNA. 
HBV DNA quantitation test were preformed using HBV DNA (primer design kit) and used real times PCR 
detection (q tower for analytic gene company, Germany). 
 Quantitative of HCV RNA 
3. Results 
Anti-HCV was positive in 12 out of 60 (20%), while patients, HBSAg was positive in 10 out of 60(16.6%) 
patients. But other HBV serological marks was positive anti-HBs, 40 out of 60(66%), anti-HBC 5 out of 
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10(50%). When examination by ELISA assay shown in table (1). 
Table 1: Percent of HBV serology marker in hemadialysisi patients by ELISA assay 
Total 
No. 
Viral marker  
Anti-HCV HBSAg Anti-HBs Anti-HBcoIgM 
60 
Positive Negative Positive Negative Positive Negative Positive Negative 
12 
(20%) 
48 
(80%) 
10 
(16.6%) 
50  
(83.3%) 
40 
(66%) 
20 
(34%) 
5 
(50%) 
5 
(50%) 
This result is compatible when examination by real time technique, HCV RNA was positive in 12 out of 60 
(20%). HBV DNA was positive in 10 out of 60 (16.6%) patients. 
Table 2: The percent of positive of HCV RNA and HBV DNA in Hemodialysis patients in real time PCR. 
Total Number 
HCV RNA HBV DNA 
Positive Negative Positive Negative 
60 12(20%) 48(8%) 10(16.6%) 50(83.3%) 
According to Real time co-infection HCV and HBV was positive in 3 out of 12 (25%) patients was shown in 
table (3). 
Table  3: The percent of HCV RNA and HBV confection among hemodialysis 
Total number of HCV RNA positive Confection HCV RNA positive and HBV DNA 
positive 
12 3(25%) 
Our results also revealed no significant difference between the HCV RNA positive male (66.6%) and female 
hemodialysis patients (33.3%). The study show no significant difference in the duration of receiving blood and 
their components between the positive and negative patients as shown in table (4). The average age of HCV 
patients was 45.5 years and 46.51 years in HCV negative patients, there for no significant difference was 
observed prevalence of HCV infection and the age of patients as shown in table (4). 
Table  4: Average age and frequency of transfusions in hemodialysis patents with hepatitis C virus infection 
HCV Number of samples Average ± SD age 
(years) 
Average ± SD 
duration since last 
blood transfusion 
month 
negative 48 45.5 ± 20.44 13.5 ± 8.23 
positive 12 46.16 ± 14.52 12.5 ± 8.92 
total 60 46.5± 20.1 12.9 ± 8.89 
Our result showed that HBV DNA 10 out of 60(16.6%) was detected through the PCR study in both patients 
groups with positive and negative HCV RNA. But 3 out of 12 (25%) HCV RNA positive were HBV DNA 
positive, and 4-out of 60 (66%) patients were positive for anti-HBS. While 5 out of 10 (50%) patients and HBV 
DNA were positive for anti-HBC. 
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4. Discussion 
Similar transmission models, HCV and HBV co-infection is prevalent, in this study, HBV were detect in 
hemodialysis patients with chronic HCV patient, viral interference has been described in patients with dual 
HBV and HCV infection [8].  In the present study, a higher frequency was found a many HBV-negative patients 
than HBV, although this difference was not significant. More preside studies, such as quantitation of both viral 
genomes and genotype are needed to evaluate the interference of replication between these two viruses [9,10]. 
The mechanism of viral interference is not known, but the host immune response could be involved in mediating 
the suppressive effect of one virus on the other [8], if this is the case, viral interference between HBV and HCV 
might not occur in immune compromised hosts like hemodialysis patients. The possible routes of transmission 
of HCV in hemodialysis patients are multiple and some of them are still controversial. The frequent blood 
transfusions in this group of patients have been an important route of infection before blood testing become 
available. There is, haw ever, increasing evidence of the nosocomial transmission of HCV, as described 
previously for HBV. The sharing of equipment as mode of HCV transmission is still controversial. Recent 
studies argue against HCV transmission through the hemodialysis ultrafiltration [11]. Beneficial effect of 
isolating equipment for HCV positive patients has been described [12-14].  The significantly higher frequency 
of blood recipient among HCV positive patients compared with that among the uninfected group table (4) 
suggests that blood transfusion remains an important mode of exposure to HCV
 
[15]. However, blood 
transfusion alone cannot account for the high prevalence and incidence of HCV infection that was observed and 
nosocomial transmission of HCV map play a role in the spread of HCV in this group as described by others [16, 
17,18]. The duration of hemodialysis correlates with HCV positivity, nosocomial transmission among 
hemodialysis patients has recently been documented by molecular analysis
 
[19, 20]. The hemodialysis machine 
used in the unit studied might also play a role in HCV dissemination because of accidental contamination of the 
device for pressure testing and inadequate subsequent disinfection. On the other hand, even if no disposable 
equipment of syringes were shared in these units, multiple parental exposure and the sharing of drugs (heparin) 
among different patients could be involved in HCV transmission, on the other hand, even if transfusion has been 
the main mode of HBV and HCV transmission in the past. Nosocomial transmission now seems to play role in 
the dissemination of HCV among these patients. Recent studies have shown that strict aseptic measures can 
virtually eliminate HCV contamination, with high prevalence of HCV infection
 
[21], preventing the 
consequences of infection not only by HCV but by other non-A, non-B and non-C viruses that could circulating 
in these venally compromised patients [22,23]. With those, our results are in- compatible 
of [27] from Iran, may be the difference in number of sample or genetic factor or immune state in the patients, 
and our results are in-compatible with those (26) from Turkey. They were unable to detect HBV DNA in 
hemodialysis HCV infected patient, it is probably due to several factors such as the intermediate prevalence of 
HBV in your region and safety of blood and it is component
 
[25].  
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